Search Results - "Grygielko, Eugene T"

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype by Ivashchenko, Christine Y, Pipes, Gordon C, Lozinskaya, Irina M, Lin, Zuojun, Xiaoping, Xu, Needle, Saul, Grygielko, Eugene T, Hu, Erding, Toomey, John R, Lepore, John J, Willette, Robert N

“…Human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) have been recently derived and are used for basic research, cardiotoxicity assessment,…”
Get more information

A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator by Madauss, Kevin P, Grygielko, Eugene T, Deng, Su-Jun, Sulpizio, Anthony C, Stanley, Thomas B, Wu, Charlene, Short, Steve A, Thompson, Scott K, Stewart, Eugene L, Laping, Nicholas J, Williams, Shawn P, Bray, Jeffrey D

“…Selective progesterone receptor modulators (SPRMs) have been suggested as therapeutic agents for treatment of gynecological disorders. One such SPRM,…”
Get full text

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis by Grygielko, Eugene T, Martin, William M, Tweed, Christopher, Thornton, Peter, Harling, John, Brooks, David P, Laping, Nicholas J

“…SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has been characterized as a potent and selective inhibitor of the…”
Get more information

Osmolality: a physiological long-term regulator of lumbar sympathetic nerve activity and arterial pressure by Scrogin, K E, Grygielko, E T, Brooks, V L

“…Acute infusion of hypertonic fluid increases mean arterial pressure (MAP) in part by elevating nonrenal sympathetic activity. However, it is not known whether…”
Get full text

Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388):  A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor by Gellibert, Françoise, de Gouville, Anne-Charlotte, Woolven, James, Mathews, Neil, Nguyen, Van-Loc, Bertho-Ruault, Cécile, Patikis, Angela, Grygielko, Eugene T, Laping, Nicholas J, Huet, Stéphane

“…Inhibitors of transforming growth factor β (TGF-β) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic,…”
Get full text

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension by Abrahamsen, Christian T, Barone, Frank C, Campbell, Jr, Wallace G, Nelson, Allen H, Contino, Lisa C, Pullen, Mark A, Grygielko, Eugene T, Edwards, Richard M, Laping, Nicholas J, Brooks, David P

“…The effects of the angiotensin type 1 (AT(1)) receptor antagonist, eprosartan, were studied in a model of severe, chronic hypertension. Treatment of male…”
Get more information

Estrogen-induced stromal cell-derived factor-1 (SDF-1/ Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor α in rat uterine cells and tissues by Glace, Lindsay, Grygielko, Eugene T., Boyle, Ryan, Wang, Qi, Laping, Nicholas J., Sulpizio, Anthony C., Bray, Jeffrey D.

“…Endometriosis, defined as the presence of endometrial glands and stroma at extra-uterine sites, is a gynecological condition that affects women of reproductive…”
Get full text

Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat by Abrahamsen, Christian T, Pullen, Mark A, Schnackenberg, Christine G, Grygielko, Eugene T, Edwards, Richard M, Laping, Nicholas J, Brooks, David P

“…The role of angiotensin II (AII) and angiotensin IV (AIV) as inducers of PAI-1 expression during hypertension was studied in vivo. A 2-week infusion of AII…”
Get more information

Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists by Thompson, Scott K., Washburn, David G., Frazee, James S., Madauss, Kevin P., Hoang, Tram H., Lapinski, Leahann, Grygielko, Eugene T., Glace, Lindsay E., Trizna, Walter, Williams, Shawn P., Duraiswami, Chaya, Bray, Jeffrey D., Laping, Nicholas J.

“…Using the X-ray crystal structure of an amide-based progesterone receptor (PR) partial agonist bound to the PR ligand binding domain, a novel PR partial…”
Get full text

2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2′,3′:4,5]thieno[2,3- b]pyridine derivatives as selective progesterone receptor agonists by Wang, Yonghui, Duraiswami, Chaya, Madauss, Kevin P., Tran, Thuy B., Williams, Shawn P., Deng, Su-Jun, Graybill, Todd L., Hammond, Marlys, Jones, David G., Grygielko, Eugene T., Bray, Jeffrey D., Thompson, Scott K.

“…A novel series of 2-amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2′,3′:4,5]thieno[2,3- b]pyridine derivatives was identified as selective PR…”
Get full text

Synthesis and SAR of amino acid-derived heterocyclic progesterone receptor full and partial agonists by Hammond, Marlys, Patterson, Jaclyn R., Manns, Sharada, Hoang, Tram H., Washburn, David G., Trizna, Walter, Glace, Lindsay, Grygielko, Eugene T., Nagilla, Rakesh, Nord, Melanie, Fries, Harvey E., Minick, Douglas J., Laping, Nicholas J., Bray, Jeffrey D., Thompson, Scott K.

“…Two series of amino acid-derived heterocyclic progesterone receptor (PR) ligands are reported. Tetrazole-containing ligands behaved as potent PR partial…”
Get full text

Improving the developability profile of pyrrolidine progesterone receptor partial agonists by Kallander, Lara S., Washburn, David G., Hoang, Tram H., Frazee, James S., Stoy, Patrick, Johnson, Latisha, Lu, Qing, Hammond, Marlys, Barton, Linda S., Patterson, Jaclyn R., Azzarano, Leonard M., Nagilla, Rakesh, Madauss, Kevin P., Williams, Shawn P., Stewart, Eugene L., Duraiswami, Chaya, Grygielko, Eugene T., Xu, Xiaoping, Laping, Nicholas J., Bray, Jeffrey D., Thompson, Scott K.

“…The previously reported pyrrolidine class of progesterone receptor partial agonists demonstrated excellent potency but suffered from serious liabilities…”
Get full text

Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists by Washburn, David G., Hoang, Tram H., Frazee, James S., Johnson, Latisha, Hammond, Marlys, Manns, Sharada, Madauss, Kevin P., Williams, Shawn P., Duraiswami, Chaya, Tran, Thuy B., Stewart, Eugene L., Grygielko, Eugene T., Glace, Lindsay E., Trizna, Walter, Nagilla, Rakesh, Bray, Jeffrey D., Thompson, Scott K.

“…We have designed and synthesized a novel series of pyrrolidinones as progesterone receptor partial agonists. Compounds from this series had improved AR…”
Get full text

Ganglionic tyrosine hydroxylase and norepinephrine transporter are decreased by increased sodium chloride in vivo and in vitro by Habecker, Beth A, Grygielko, Eugene T, Huhtala, Timothy A, Foote, Billy, Brooks, Virginia L

“…The present study tested the hypothesis that, in normal male rats, chronic changes in salt intake alter the levels of tyrosine hydroxylase and the…”
Get full text

Role of caspases in human renal proximal tubular epithelial cell apoptosis by Wong, Victoria Y, Keller, Paul M, Nuttall, Mark E, Kikly, Kristine, DeWolf, Walter E, Lee, Dennis, Ali, Shujath M, Nadeau, Daniel P, Grygielko, Eugene T, Laping, Nicholas J, Brooks, David P

“…In the present study, we have used an in vitro model of apoptosis using primary human renal proximal tubular epithelial (RPTE) cells to investigate the…”
Get full text

Compensatory role for Sgk2 mediated sodium reabsorption during salt deprivation in Sgk1 knockout mice by Schnackenberg, Christine G, Costell, Melissa H., Bernard, Roberta E., Minuti, Kristine K., Grygielko, Eugene T., Parsons, Michael J., Laping, Nicholas J., Duddy, Graham

“…The purpose of this study was to investigate the role of Sgk2 in the regulation of salt and water homeostasis. Kidney function and expression of Sgk1, Sgk2,…”
Get full text